4.8 Article

RNA-Based Immunostimulatory Liposomal Spherical Nucleic Acids as Potent TLR7/8 Modulators

期刊

SMALL
卷 14, 期 49, 页码 -

出版社

WILEY-V C H VERLAG GMBH
DOI: 10.1002/smll.201803284

关键词

cancer vaccine; immunomodulation; liposome; nanoparticle; SNAs; spherical nucleic acids; TLR7/8 agonist

资金

  1. National Cancer Institute of the National Institutes of Health [U54CA199091]
  2. Prostate Cancer Foundation [17CHAL08]
  3. Movember Foundation [17CHAL08]
  4. NTU-NU Institute for NanoMedicine located at the International Institute for Nanotechnology, Northwestern University, USA
  5. Nanyang Technological University, Singapore
  6. Department of Defense (DoD) through the National Defense Science & Engineering Graduate Fellowship (NDSEG) Program
  7. Northwestern University's Cancer Nanotechnology Training Program [T32CA186897]
  8. NCI CCSG [P30 CA060553]

向作者/读者索取更多资源

Immunostimulatory spherical nucleic acids (IS-LSNAs) comprised of RNA selective for toll-like receptors (TLRs) 7/8 are synthesized and characterized. These structures consist of liposomal cores functionalized with a dense shell of RNA inserted into the wall of the lipid core via hydrophobic cholesterol moieties. IS-LSNAs potently activate TLR7/8 via NF-kappa B signaling in reporter cell lines and in primary immune cells as evidenced by cytokine production and the upregulation of costimulatory receptors. Importantly, they are preferentially taken up by plasmacytoid dendritic cells, an observation that makes them potentially useful for immunotherapy. In addition, these structures contain a core that can be loaded with antigens and used to prime T cells. In this regard, it is shown that dendritic cells treated with IS-SNAs loaded with ovalbumin peptide can prime ova specific CD8(+) T cells. In addition to introducing the first IS-LSNAs consisting of RNA, these experiments show that one can facilitate an antigen-specific T cell response greater than that of free or cationic lipid-transfected RNA of the same sequence selective for TLR7/8. This work points toward the promise of using IS-LSNAs comprised of RNA as potent and highly tunable TLR-specific agents for the development of vaccines and other pharmaceuticals that require selective immunomodulation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据